Learn more about our Payment & Health Care Delivery Policy work.
It is critical for diagnostic test developers to demonstrate the value of their tests to a variety of stakeholders. This framework serves as a resource for members to assess and…
From MDUFA V and the major investments in semiconductor chip manufacturing in the CHIPS Act, to addressing global supply chain issues and supporting our AdvaMed Accel® companies, 2022 was a…
Cary Vance, President and CEO of Titan Medical, joined AdvaMed®’s Scott Whitaker on the Medtech POV podcast to share his experience leading a small medical device company through the regulatory…
CEO and surgeon Dr. Lishan Aklog speaks about the tremendous value of medical technology, the sharp disparities patients face, and the importance of policymaking to ease those disparities.
AdvaMed® submitted comments to CMS on the CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule.
AdvaMed® submitted comments to CMS on the Calendar Year 2023 Physician Fee Schedule (PFS) proposed rule.
AdvaMed® submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.
AdvaMed® submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
The Advanced Medical Technology Association® (AdvaMed®), the world’s largest trade association representing medical device manufacturers, urged the U.S. Centers for Medicare & Medicaid Services (CMS) to issue its proposed Transitional…
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.